Sarepta's Expanded FDA Approval For Elevidys Potentially Shaping Future FDA Reviews, Analyst Says
Sarepta Therapeutics,, Inc. Common Stock · PHARMACEUTICAL PREPARATIONS · Now $17.61
-2.2% in 1d after detection
Post-detection moves
1h
—
1d
-2.2%
3d
-0.3%
7d
+1.7%
30d
—
Get alerts like this in real time
Push notifications the moment a signal fires. No spam, no crypto, no fluff.
Download for iOS